Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 12 2019
Historique:
received: 18 07 2019
revised: 07 08 2019
accepted: 11 08 2019
pubmed: 31 8 2019
medline: 6 2 2020
entrez: 31 8 2019
Statut: ppublish

Résumé

Randomized data assessing the longitudinal quality of life (QoL) impact of stereotactic ablative radiation therapy (SABR) in the oligometastatic setting are lacking. We enrolled patients who had a controlled primary malignancy with 1 to 5 metastatic lesions, with good performance status and life expectancy >6 months. We randomized in a 1:2 ratio between standard of care (SOC) treatment (SOC arm) and SOC plus SABR to all metastatic lesions (SABR arm). QoL was measured using the Functional Assessment of Cancer Therapy-General. QoL changes over time and between groups were assessed with linear mixed modeling. Ninety-nine patients were randomized. Median age was 68 years (range, 43-89), and 60% were male. The most common primary tumor types were breast (n = 18), lung (n = 18), colorectal (n = 18), and prostate (n = 16). Most patients (n = 92) had 1 to 3 metastases. Median follow-up was 26 months. Because of the previously reported inferior survival of the SOC arm, the time for attrition in QoL respondents to <10% of subjects was shorter in the SOC versus SABR arm (30 vs 42 months). In the whole cohort, QoL declined over time after randomization: There were significant declines in total Functional Assessment of Cancer Therapy-General score over time compared with baseline (P < .001) owing to declines in physical and functional subscales (both P < .001), with no declines in social and emotional subscales. However, the magnitudes of decline were small, and clinically meaningful changes were not seen at most time points. Comparison between arms showed no differences in QoL between the SABR and SOC arms in total score (P = .42) or in the physical (P = .98), functional (P = .59), emotional (P = .82), or social (P = .17) subscales. For patients with oligometastases, average QoL declines slowly over time regardless of treatment approach, although the changes are small in magnitude. The use of SABR, compared with SOC, was not associated with a QoL detriment.

Identifiants

pubmed: 31470091
pii: S0360-3016(19)33690-9
doi: 10.1016/j.ijrobp.2019.08.041
pii:
doi:

Types de publication

Clinical Trial, Phase II Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

943-947

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Robert Olson (R)

BC Cancer-Centre for the North, Prince George, British Columbia, Canada. Electronic address: rolson2@bccancer.bc.ca.

Suresh Senan (S)

VU University Medical Center, Amsterdam, Netherlands.

Stephen Harrow (S)

Beatson West of Scotland Cancer Centre, Glasgow, Scotland.

Stewart Gaede (S)

London Health Sciences Centre, London, Ontario, Canada.

Alexander Louie (A)

Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.

Cornelis Haasbeek (C)

VU University Medical Center, Amsterdam, Netherlands.

Liam Mulroy (L)

Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada.

Michael Lock (M)

London Health Sciences Centre, London, Ontario, Canada.

George Rodrigues (G)

London Health Sciences Centre, London, Ontario, Canada.

Brian Yaremko (B)

London Health Sciences Centre, London, Ontario, Canada.

Devin Schellenberg (D)

BC Cancer-Surrey, Surrey, British Columbia, Canada.

Belal Ahmad (B)

London Health Sciences Centre, London, Ontario, Canada.

Gwendolyn Griffioen (G)

VU University Medical Center, Amsterdam, Netherlands.

Sashendra Senthi (S)

Alfred Hospital, Melbourne, Australia.

Anand Swaminath (A)

Juravinski Cancer Centre, Hamilton, Ontario, Canada.

Neil Kopek (N)

McGill University Health Centre, Montreal, QC, Canada.

Mitchell Liu (M)

BC Cancer-Vancouver, Vancouver, British Columbia, Canada.

Karen Moore (K)

Beatson West of Scotland Cancer Centre, Glasgow, Scotland.

Suzanne Currie (S)

Beatson West of Scotland Cancer Centre, Glasgow, Scotland.

Glenn Bauman (G)

London Health Sciences Centre, London, Ontario, Canada.

Andrew Warner (A)

London Health Sciences Centre, London, Ontario, Canada.

David Palma (D)

London Health Sciences Centre, London, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH